Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal ...
Published at : 27 Jan 2021
Dr Josep Tabernero presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from the KEYNOTE-062 trial.
The trial reached its primary endpoint, showing that overall survival for pembrolizumab was non-inferior (comparable) to standard chemotherapy.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.